AIQ GlobalIn honor of Women’s History Month, AIQ Solutions is proud to recognize some of the incredible women helping advance what is possible in medicine and improve how care is delivered to patients with cancer.
Across clinical, technical, and partnership roles, these individuals contribute to the development and adoption of TRAQinform IQ technology. Their work supports clinicians with clearer, more reliable insights to help guide treatment decisions.
AIQ Solutions is proud to share that we have secured a sixth patent for our AI-enabled late-stage cancer analysis technology (U.S. Patent No. 12,562,258).
CPT code is a major milestone to scale late-stage cancer analysis technology across the healthcare system
AIQ Solutions today announced a significant advancement in the fight against late-stage cancer. After years of rigorous clinical, regulatory, and operational work by AIQ, the American Medical Association (AMA) has approved a new Category III Current Procedural Terminology (CPT) code describing the unique output of AIQ’s TRAQinform IQ technology. This milestone will help make advanced treatment response intelligence more accessible to oncologists and the patients who need it most.
AIQ Solutions technology is featured in the Journal of Nuclear Medicine as a highlight of the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. https://jnm.snm
Technical Advancements in Clinical Learning- What’s New in 2021 Revolutionizing Precision Medicine One Lesion at a Time
Automated Evaluation of Disease on 68Ga-DOTATATE PET/CT Images for Long-term Lesion Tracking on 177Lu-DOTATATE Therapy
RALEIGH, N.C., June 9, 2022 /PRNewswire/ — Lucem Health™ today launched the Lucem Health Innovation Collaborative, a partner program designed to move clinical AI/ML innovation to the front lines of healthcare. The Collaborative will help digital health innovators create, deploy, and commercialize transformational solutions powered by artificial intelligence and machine learning models.
“Imaging biomarkers to better evaluate and predict treatment response for complex diseases.” Company Presentation Theater 2 Wednesday, June 15, 2022 4:00 pm- 4:15 pm ( PDT)